ZEALAND PHARMA A S's ticker is ZEAL and the CUSIP is 98920Y304. A total of 15 filers reported holding ZEALAND PHARMA A S in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $4,000 | -69.2% | 351 | -60.9% | 0.00% | – |
| Q1 2022 | $13,000 | -38.1% | 897 | -6.3% | 0.00% | – |
| Q4 2021 | $21,000 | +425.0% | 957 | +564.6% | 0.00% | – |
| Q3 2021 | $4,000 | +300.0% | 144 | +380.0% | 0.00% | – |
| Q2 2021 | $1,000 | -97.4% | 30 | -97.5% | 0.00% | – |
| Q1 2021 | $38,000 | +3700.0% | 1,203 | +3910.0% | 0.00% | – |
| Q4 2020 | $1,000 | 0.0% | 30 | 0.0% | 0.00% | – |
| Q3 2020 | $1,000 | 0.0% | 30 | 0.0% | 0.00% | – |
| Q2 2020 | $1,000 | -97.5% | 30 | -97.4% | 0.00% | – |
| Q1 2020 | $40,000 | +110.5% | 1,153 | +52.5% | 0.00% | – |
| Q3 2019 | $19,000 | +35.7% | 756 | +17.2% | 0.00% | – |
| Q2 2019 | $14,000 | -65.9% | 645 | -73.2% | 0.00% | – |
| Q1 2019 | $41,000 | +41.4% | 2,407 | -3.5% | 0.00% | – |
| Q4 2018 | $29,000 | +38.1% | 2,494 | +94.4% | 0.00% | – |
| Q3 2018 | $21,000 | +5.0% | 1,283 | -20.3% | 0.00% | – |
| Q2 2018 | $20,000 | +300.0% | 1,610 | +481.2% | 0.00% | – |
| Q3 2017 | $5,000 | – | 277 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT LLC | 510,000 | $18,329,000 | 0.11% |
| AWM Investment Company, Inc. | 19,981 | $718,000 | 0.09% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 5,653 | $203,000 | 0.06% |
| WELLINGTON MANAGEMENT GROUP LLP | 1,099,546 | $39,517,000 | 0.01% |
| ROYCE & ASSOCIATES LP | 10,000 | $359,000 | 0.00% |
| Winslow, Evans & Crocker, Inc. | 235 | $8,000 | 0.00% |
| Renaissance Technologies | 17,205 | $618,000 | 0.00% |
| JANE STREET GROUP, LLC | 35,707 | $1,283,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| Parallel Advisors, LLC | 94 | $3,000 | 0.00% |